XueBiJing is an intravenous five-herb injection used to treat sepsis in China.The study aimed to develop a liquid chromatography-tandem mass spectrometry(LC-MS/MS)-or liquid chromatography-ultraviolet(LC-UV)-based assay for quality evaluation of XueBiJing.Assay development involved identifying marker constituents to make the assay therapeutically relevant and building a reliable one-point cali-brator for monitoring the various analytes in parallel.Nine marker constituents from the five herbs were selected based on XueBiJing's chemical composition,pharmacokinetics,and pharmacodynamics.A selectivity test(for"similarity of response")was developed to identify and minimize interference by non-target constituents.Then,an intercept test was developed to fulfill"linearity through zero"for each analyte(absolute ratio of intercept to C response,＜2％).Using the newly developed assays,we analyzed samples from 33 batches of XueBiJing,manufactured over three years,and found small batch-to-batch variability in contents of the marker constituents(4.1％-14.8％),except for senkyunolide I(26.5％).

OBJECTIVE: To explore the role of Ca-NFAT signaling pathway in Ph-ALL drug resistance mediated by bone marrow stromal cells. METHODS: The transcription level of NFAT mRNA in Sup-B15 cells and Ph ALL primary cells was detected by polymerase chain reaction. The expression of P-glycoprotein in Sup-B15 cells was detected by flow cytometry. The change of NFAT protein in Sup-B15 cells was detected by Western blot. AnnexinV/7-AAD was used to label cells. Flow cytometry was used to detect cell apoptosis; Fluo 3-AM dye was used to label cells, and flow cytometry used to detect changes of Ca concentration in leukemia cells. RESULTS NFAT expression could be detected in both Sup-B15 and Ph ALL primary cells; P-glycoprotein could not be detected by flow cytometry; CAS could significantly inhibit NFAT protein expression in clinically applied drug concentrations (2.5, 5 μmol/L); Clinically applied concentration of CAS (2.5, 5 μmol / L) has no significant effect on the apoptosis of Sup-B15 cells, while higher concentration of CAS (10 μmol / L) could induce apoptosis of Sup-B15 cells. Bone marrow stromal cells OP9 could, decrease the sensitivity of Sup-B15 cells and Ph ALL primary cells to imatinib (IM); After co-culture with bone were marrow stromal cells, the Ca concentration in Sup-B15 cells was enhanced, the levels of NFAT protein and nullear protein in sup-B15 cells also were enhanced. The addition of CAS in co-culture system could inlibit the Ca-NFAT signaling pathway, reduce the protective effect of OP9 on Sup-B15 cells.Conclution:The Ca-NFAT sigualing pathway, contributes to the survival of Ph ALL cells. Bone marrow stromal cells can mediate the resistance of Ph ALL cells to IM by activating Ca-NFAT signaling pathway.
Bone Marrow Cells ; Cell Line, Tumor ; Humans ; Imatinib Mesylate ; Mesenchymal Stem Cells ; NFATC Transcription Factors ; Precursor Cell Lymphoblastic Leukemia-Lymphoma ; Signal Transduction

Objective To explore the effect of hyperbaric oxygen(HBO) on QT dispersion in patients with diabetes. Methods One hundred and two cases of type Ⅱ diabetes patients were divided into the HBO treatment group, i.e. HBO therapy combined with conventional therapy (60 cases) and the conventional therapy control group (42 cases). The HBO treatment group who were to undergo 20 sessions of HBO therapy in 4 weeks, were enrolled in the study. Heart rate, blood pressure, cardiac ejection fraction, serum potassium,fasting blood - glucose and glycosylated hemoglobin were measured both before HBO therapy and after 20 sessions of HBO therapy. At the same time, ECG was made to monitor QT intervals, QTd and QTcd. Results QTc dispersion decreased significantly from(59. 8 ± 17.4) ms to (52. 2± 15.5) ms following 20 sessions of HBO therapy, when they were compared with those of the conventional therapy group (P < 0. 05).Conclusions HBO treatment could decrease QT dispersion in patients with diabetes, and reduce risks of malignant ventricular arrhythmia and sudden cardiac death.

Objective To explore the effect of hyperbaric oxygen(HBO) on QT dispersion in patients with diabetes. Methods One hundred and two cases of type Ⅱ diabetes patients were divided into the HBO treatment group, i.e. HBO therapy combined with conventional therapy (60 cases) and the conventional therapy control group (42 cases). The HBO treatment group who were to undergo 20 sessions of HBO therapy in 4 weeks, were enrolled in the study. Heart rate, blood pressure, cardiac ejection fraction, serum potassium,fasting blood - glucose and glycosylated hemoglobin were measured both before HBO therapy and after 20 sessions of HBO therapy. At the same time, ECG was made to monitor QT intervals, QTd and QTcd. Results QTc dispersion decreased significantly from(59. 8 ± 17.4) ms to (52. 2± 15.5) ms following 20 sessions of HBO therapy, when they were compared with those of the conventional therapy group (P < 0. 05).Conclusions HBO treatment could decrease QT dispersion in patients with diabetes, and reduce risks of malignant ventricular arrhythmia and sudden cardiac death.